Antitumor triptycene bisquinones: A novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities

Anti-Cancer Drugs

Volumn 14, Issue 7, 2003, Pages 503-514

  Wang, Buna ^a   Perchellet, Elisabeth M ^a   Wang, Yang ^a   Tamura, Masafumi ^a   Hua, Duy H ^a   Perchellet, Jean Pierre H ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Antitumor drugs; Dual inhibitors; Topoisomerase activities; Triptycene bisquinones

Indexed keywords

6 BROMO 7 METHOXY 2 N METHYLAMINO 1H,4H,5H,8H 9,10 DIHYDRO 9,10 [1',2']BENZENOANTHRACENE 1,4,5,8 TETRAONE; 7 BROMO 6 METHOXY 2 N METHYLAMINO 1H,4H,5H,8H 9,10 DIHYDRO 9,10 [1',2']BENZENOANTHRACENE 1,4,5,8 TETRAONE; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; PLASMID DNA; TRIPTYCENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; MOLECULAR WEIGHT; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES; ENZYME INHIBITORS; HUMANS; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0041831131     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200308000-00002     Document Type: Article

References (62)

1. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. Quinone chemistry and toxicity. Toxicol Appl Pharmacol 1992; 112:2-16.
2. Myers CE, Chabner BA. Anthracyclines. In: Chabner BA, Collins JM (editors): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott; 1990, pp. 356-381.
3. 2/M cell cycle arrest and apoptosis. Free Rad Biol Med 1998; 24:848-854.
4. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-375.
5. Ganapathi R, Grabowski D, Hoeltge G, Neelon R. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells. Biochem Pharmacol 1990; 40:1657-1662.
6. Ling Y-H, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 1993; 53:1845-1852.
7. Ramachandran C, You W, Krishan A. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells. Anticancer Res 1997; 17:3369-3376.
8. Perchellet EM, Magill MJ, Huang X, Brantis CE, Hua DH, Perchellet JP. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro. Anticancer Drugs 1999; 10:749-766.
9. Perchellet EM, Sperfslage BJ, Wang Y, et al. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro. Anticancer Drugs 2002; 13:567-582.
10. Wang B, Wu M, Perchellet EM, et al. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubiein-resistant HL-60 cell lines. Int J Oncol 2001; 19:1169-1178.
11. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256:12-18.
12. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997; 75:337-349.
13. Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001; 477:97-110.
14. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-809.
15. Kaufmann SH. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 1996; 2:298-303.
16. Wang Y, Perchellet EM, Tamura M, Hua DH, Perchellet JP. Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines. Cancer Lett 2002; 188:73-83.
17. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21429-21432.
18. Pommier Y. DNA topoisomerases and their inhibition by anthracyclines. In: Priebe W (editor): Anthracycline Antibiotics. New Analogues, Methods of Delivery, and Mechanisms of Action (ACS Syrup Ser 574). Washington, DC: American Chemical Society; 1995, pp. 183-203.
19. Kohn KW. Beyond DNA cross-linking: history and prospect of DNA-targeted cancer treatment. Fifteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1996; 56:5533-5546.
20. Roy C, Brown DL, Little JE, et al. The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes. Exp Cell Res 1992; 200:416-424.
21. Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1993; 1175:147-154.
22. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001; 41:53-77.
23. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-5082.
24. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-6368.
25. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990; 50:6919-6924.
26. Riou J-F, Fossé P, Nguyen CH, et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res 1993; 63:5987-5993.
27. Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA topoisomerase I and II-mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 1991; 30:5838-5845.
28. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol 1990; 38:38-45.
29. Larsen AK, Grondard L, Couprie J, et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmcol 1993; 46:1403-1412.
30. Riou JF, Helissey P, Grondard L, Giorgi-Renault S. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol Pharmacol 1991; 40:699-706.
31. Utsugi T, Aoyagi K, Asao T, et al. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997; 88:992-1002.
32. Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996; 32A:708-714.
33. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13:15-28.
34. Perrin D, vanHille B, Barret J-M, et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism action. Biochem Pharmacol 2000; 59:807-819.
35. Etiévant C, Kruczynski A, Barret J-M, Perrin D, Hill BT. Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II. Biochem Pharmacol 2003; 65:755-763.
36. Umemura K, Mizushima T, Katayama H, Kiryu Y, Yamori T, Andoh T. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities. Mol Pharmacol 2002; 62:873-880.
37. Mizushina Y, Murakami C, Ohta K, et al. Selective inhibition of the activities of both eukaryotic DNA polymerases and DNA topoisomerases by elenic acid. Biochem Pharmacol 2002; 63:399-407.
38. Constantinou A, Stoner GD, Mehta R, Rao K, Runyan C, Moon R. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutr Cancer 1996; 23:121-130.
39. Yakisich JS, Sidén Å, Enereth P, Cruz M. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 2001; 289:586-590.
40. Hua DH, Tamura M, Huang X, et al. Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones. Unusual reactivities with amines. J Org Chem 2002; 67:2907-2912.
41. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3:207-212.
42. Spitzner JR, Chung IK, Muller MT. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res 1990; 18:1-11.
43. Powis G. Free radical formation by antitumor quinones. Free Rad Biol Med 1989; 6:63-101.
44. Nitiss JL. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 1998; 1400:63-81.
45. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3:430-440.
46. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70:369-413.
47. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400:83-105.
48. Palumbo M, Gatto B, More S, Sissi C, Zagotto G. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim Biophys Acta 2002; 1587:145-154.
49. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379:225-232.
50. Topcu Z. DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 2001; 26:405-416.
51. Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002; 20:570-589.
52. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991; 30:1807-1813.
53. Cline SD, Macdonald TL, Osheroff N. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Biochemistry 1997; 36:13095-13101.
54. Gellert M, Fisher LM, O'Dea MH. DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein. Proc Natl Acad Sci USA 1979; 76:6289-6293.
55. Sugino A, Higgins NP, Brown PC, Peebles CL, Cozzarelli NR. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci USA 1978; 75:4838-4842.
56. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell 1985; 41:553-563.
57. Muller MT, Helal K, Soisson S, Spitzner JR. A rapid and quantitative microtiter assay for eukaryotic topoisomerase II. Nucleic Acids Res 1989; 17:9499.
58. Muller MT. Quantitation of eukaryotic topoisomerase I reactivity with DNA. Preferential cleavage of supercoiled DNA. Biochim Biophys Acta 1985; 824:263-267.
59. Crow RT, Crothers DM. Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA-binding agents. J Med Chem 1994; 37:3191-3194.
60. Grad JM, Cepero E, Boise LH. Mitochondria as targets for established and novel anti-cancer agents. Drug Resistance Updates 2001; 4:85-91.
61. Trask DK, Muller MT. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988; 85:1417-1421.
62. Nitiss J L, Pourquier P, Pommier Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 1997; 57:4564-4569.